Last June, Amgen excited cancer scientists and investors alike with the first tumor-shrinking results from a medicine targeted against the “undruggable” KRAS protein.
On Sunday, the biotech presented another round of data on the KRAS-blocking drug called AMG 510. Like this past summer, tumor responses hover around 50% — more impressive now because the analysis comprises a larger number of lung cancer patients. But the details also reveal some questions about AMG 510 that will require further time and study to answer.
About the Author Reprints
